SCHEDULE 13G/A: Capital International Investors Discloses 5.8% Passive Stake in BeiGene, Ltd.
Beneficial Ownership Report
Capital International Investors has filed an amended Schedule 13G, disclosing a 5.8% beneficial ownership stake in BeiGene, Ltd. as of March 31, 2025.
Summary
- Capital International Investors (CII) reported beneficial ownership of 81,647,620 shares of BeiGene, Ltd. Common Stock.
- This ownership represents 5.8% of the 1,400,455,662 shares of BeiGene, Ltd. believed to be outstanding.
- CII holds sole voting power over 80,458,292 shares and sole dispositive power over 81,647,620 shares.
- The filing is an Amendment No. 5 to Schedule 13G, indicating an update to previously reported ownership.
- The shares include 5,903,798 Depository Receipts, which represent 76,749,374 Common Stock.
- CII certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of BeiGene, Ltd.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing passive ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
The document is a regulatory filing disclosing ownership and does not contain forward-looking statements or guidance from BeiGene, Ltd. or Capital International Investors regarding the issuer's future performance.
Industry Context
This filing indicates a significant institutional investment by Capital International Investors in BeiGene, Ltd., a company operating in the biotechnology and pharmaceutical sector. Such disclosures provide transparency on major ownership stakes within the industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership in BeiGene, Ltd.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement (reporting date for ownership calculation). |
| 05/02/2025 | Date of signature and filing of the Schedule 13G Amendment No. 5. |
Keywords
BeiGene, Capital International Investors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.